# EDGAR Filing Document

**Accession Number:** 0001969365
**File Stem:** 0001209191-23-020159
**Filing Date:** 2023-3
**Character Count:** 9444
**Document Hash:** 29557c1e1fe603a0f83d8b308c682275
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001209191-23-020159.hdr.sgml**: 20230321

**ACCESSION NUMBER**: 0001209191-23-020159

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20230313

**FILED AS OF DATE**: 20230321

**DATE AS OF CHANGE**: 20230321

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Pimblett Emily
- **CENTRAL INDEX KEY:** 0001969365

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40708
- **FILM NUMBER:** 23748246

**MAIL ADDRESS:**
- **STREET 1:** C/O ELIEM THERAPEUTICS, INC.
- **STREET 2:** 23515 NE NOVELTY HILL RD, STE B221 #125
- **CITY:** REDMOND
- **STATE:** WA
- **ZIP:** 98053
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Eliem Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001768446
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 832273741
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 23515 NE NOVELTY HILL ROAD
- **STREET 2:** SUITE B221 #125
- **CITY:** REDMOND
- **STATE:** WA
- **ZIP:** 98053
- **BUSINESS PHONE:** 877-354-3689

**MAIL ADDRESS:**
- **STREET 1:** 23515 NE NOVELTY HILL ROAD
- **STREET 2:** SUITE B221 #125
- **CITY:** REDMOND
- **STATE:** WA
- **ZIP:** 98053

## Ex-24

```
<PRE>
POWER OF ATTORNEY
	Know all by these presents that the undersigned hereby constitutes and appoints
each of Alan Hambelton, Julia Stark, William Cowles and Brian Woodard of Cooley
LLP, signing individually, the undersigned's true and lawful attorneys-in-fact
and agents to:
	(1)	prepare, execute in the undersigned's name and on the undersigned's behalf,
and submit to the Securities and Exchange Commission (the "SEC") a Form ID,
including amendments thereto, and any other documents necessary or appropriate
to obtain codes and passwords enabling the undersigned to make electronic
filings with the SEC of reports required by Section 16(a) of the Securities
Exchange Act of 1934 or any rule or regulation thereunder;

	(2)	prepare, execute in the undersigned's name and on the undersigned's behalf,
and submit to the SEC Forms 3, 4 and 5 (including amendments thereto and joint
filing agreements in connection therewith) in accordance with Section 16(a) of
the Securities Exchange Act of 1934 and the rules thereunder;

	(3)	do and perform any and all acts for and on behalf of the undersigned that
may be necessary or desirable to prepare and execute any such Form 3, 4 or 5
(including amendments thereto and joint filing agreements in connection
therewith) and file such Forms with the SEC and any stock exchange,
self-regulatory association or any other authority; and

	(4)	take any other action of any type whatsoever in connection with the
foregoing that, in the opinion of such attorney-in-fact, may be of benefit to,
in the best interest of, or legally required of the undersigned, it being
understood that the documents executed by the attorney-in-fact on behalf of the
undersigned pursuant to this Power of Attorney shall be in such form and shall
contain such terms and conditions as the attorney-in-fact may approve in the
attorney-in-fact's discretion.

	The undersigned hereby grants to each such attorney-in-fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary, or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney-in-fact, or such
attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be
done by virtue of this power of attorney and the rights and powers herein
granted.  The undersigned acknowledges that the foregoing attorneys-in-fact, and
their substitutes, in serving in such capacity at the request of the
undersigned, are not assuming (nor is Eliem Therapeutics, Inc. (the "Company")
assuming) any of the undersigned's responsibilities to comply with Section 16 of
the Securities Exchange Act of 1934.

	This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4 and 5 with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to the
Company and the attorneys-in-fact.

	IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of the date written below.

Dated:  March 9, 2023

By: /s/ Emily Pimblett				Emily Pimblett
	Signature					Printed Name

</PRE>
```

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Pimblett Emily<br><sub>(Last) (First) (Middle)</sub><br>C/O ELIEM THERAPEUTICS, INC.<br>23515 NE NOVELTY HILL RD, STE. B221 #125<br><sub>(Street)</sub><br>REDMOND, WA 98053<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>Eliem Therapeutics, Inc. [ ELYM ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2023-03-13 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [ ] 10% Owner<br>[X] Officer (give title below)   [ ] Other (specify below)<br>_Chief Accounting Officer_ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Stock Option (Right to Buy) | <sup>(1)</sup> | 2031-04-26 | Common Stock | 35000 | $6.10 | D |  |
| Stock Option (Right to Buy) | <sup>(2)</sup> | 2032-01-26 | Common Stock | 30000 | $8.21 | D |  |
| Stock Option (Right to Buy) | <sup>(3)</sup> | 2032-10-30 | Common Stock | 30000 | $3.27 | D |  |

---

### Footnotes:

(1) The shares subject to this option shall vest at a rate of 12/48ths of the total number of shares on the one-year anniversary of March 26, 2021 (the "March 2021 Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the March 2021 Vesting Commencement Date thereafter for so long as the Reporting Person remains an officer, director, employee, consultant and/or advisor of the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the March 2021 Vesting Commencement Date.

(2) The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of January 27, 2022 (the "January 2022 Vesting Commencement Date") for so long as the Reporting Person remains an officer, director, employee, consultant and/or advisor of the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the January 2022 Vesting Commencement Date.

(3) The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of October 31, 2022 (the "October 2022 Vesting Commencement Date") for so long as the Reporting Person remains an officer, director, employee, consultant and/or advisor of the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the October 2022 Vesting Commencement Date.

**Signature:** /s/ Brian Woodard, Attorney-in-Fact  
**Date:** 2023-03-21

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**